Artificial Intelligence
With 39% CAGR, AI in Drug Discovery Market Size Surge to USD 485 Million By 2026: Facts & Factors
New York, NY, March 17, 2021 (GLOBE NEWSWIRE) — Facts and Factors have published a new research report titled “AI in Drug Discovery Market By Drug Type (Small Molecule and Large Molecule), By Technology (Deep Learning, Machine Learning, Others), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Academic & Research Institutes, and Others), By Therapeutic Area (Metabolic Diseases, Cardiovascular Diseases, Immuno-Oncology, Oncology, Neurodegenerative Diseases, Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020–2026”.
“According to the research report, the global AI in Drug Discovery Market was estimated at USD 830 Million in 2019 and is expected to reach USD 12,000 Million by 2026. The global AI in Drug Discovery Market is expected to grow at a compound annual growth rate (CAGR) of 39% from 2020 to 2026”.
Artificial Intelligence is a machine, device, or company method for learning about how smart human thought is and that research eventually develops intelligent software systems. Modularizing artificial intelligence with health-care tools in pharmaceutical, biopharmaceutical companies, and drug discovery research organizations is called drug discovery AI. Machine learning and other innovations will allow pursuing new pharmaceuticals quicker, cheaper, and more successful. Drug companies rapidly understand the importance of introducing systems focused on Artificial Intelligence (AI) that can exploit data on gene variants, receptor targets, metabolic enzymes, disease events, and clinical studies to find hidden associations in drug-disease. One of the drivers for the market could be the growing demand for genetic data analysis and customized medication. Machine learning could help enhance treatment by incorporating biomedical and scientific statistics with computational models and can be used to build software to check drugs and other therapies. Some computational replicas and tactics that sustenance the accumulation of clinical statistics are under progress and are moreover a few very good examples of successful data integration in biology and medicine. One of the possible alternatives is to interpret the genetic makeup as a one-dimensional model and then to implement a regular algorithm for machine learning.
Request Your Free Sample Report of AI in Drug Discovery Market @ https://www.fnfresearch.com/sample/ai-in-drug-discovery-market
(The free sample of this report is readily available on request).
Our Free Sample Report Includes:
- 2020 Updated Report Introduction, Overview, and In-depth industry analysis
- COVID-19 Pandemic Outbreak Impact Analysis Included
- 190+ Pages Research Report (Inclusion of Updated Research)
- Provide Chapter-wise guidance on Request
- 2020 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
- Includes Updated List of table & figures
- Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
- Facts and Factors research methodology
(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)
Key Questions Answered in this Report
1) What were the pre and post-business impacts of COVID-19 on the AI in Drug Discovery Market?
2) What is the market size, share of AI in Drug Discovery Market?
3) Who are the top market players in AI in Drug Discovery Market?
4) What will be the future market of AI in Drug Discovery Market?
Key Offerings:
- Market Size & Forecast by Revenue | 2020−2026
- Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunities
- Market Segmentation – A detailed analysis by product, by types, end-user, applications, segments, and geography
- Competitive Landscape – Top key vendors and other prominent vendors
Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/ai-in-drug-discovery-market
(You may enquire a report quote OR available discount offers to our sales team before purchase.)
Impact Analysis of COVID-19 Pandemic on Businesses: Know Short Term and Long Term Impact
Most of the businesses are facing a growing litany of business-critical concerns related to the coronavirus outbreak, including supply chain disruptions, a risk of a recession, and a potential drop in consumer spending. All these scenarios will play out differently across various regions and industries, making accurate and timely market research more essential than ever.
We at Facts and Factors (http://www.fnfresearch.com) understand how difficult it is for you to plan, strategize, or make business decisions, and as such, we have your back to support you in these uncertain times with our research insights. Our team of consultants, analysts, and experts has developed an analytical model tool for markets that helps us to assess the impact of the virus more effectively on the industrial markets. We are further implementing these insights into our reports for a better understanding of our clients.
Request Pre and Post COVID-19 Impact Analysis on Businesses: https://www.fnfresearch.com/sample/ai-in-drug-discovery-market
Another driver for the market is Quantum machine learning research indicating this method should be useful for finding complex patterns in results. Given the complexity of biological and clinical details, deterministic quantic machine learning algorithms represent a real chance to better know them. The introduction of a novel machine-learning algorithm for drug discovery in the near future is expected to generate an immense opportunity for the growth of the market in the near future. In the near future, the increasing relationship between pharmaceutical companies and AI-based companies to automate the drug discovery approach is expected to generate huge opportunities for company growth.
Industry Major Market Players
- Atomwise Inc
- BenevolentAI
- Bio age
- Cloud Pharmaceuticals Inc
- Exscientia Ltd
- Insilico Medicine Inc
- Numerate Inc
- Envisagenics Inc
- Two XAR Inc
- Accutar Biotechnology Inc
- Recursion Pharmaceuticals Inc
- Silicon Therapeutics LLC
- AstraZeneca PLC.
To know an additional revised 2020 list of market players, request a sample report: https://www.fnfresearch.com/sample/ai-in-drug-discovery-market
One of the major challenges in the drug discovery phase is patient health. Dynamic activities are to interpret information about the documented effects of drugs and anticipate their side effects which will be a restraint for the market.
One of the major challenges in the drug discovery phase is patient health. Dynamic activities are to interpret information about the documented effects of drugs and anticipate their side effects which will be a restraint for the market.
Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/ai-in-drug-discovery-market
The study provides a decisive view of the AI in the Drug Discovery market by segmenting the AI in the Drug Discovery market based on drug type, technology, end-user, therapeutic area, and regions. All the segments and sub-segments have been examined based on historic, current, and future trends in the global market and the market size is estimated from 2020 to 2026 in terms of value. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
An AI in Drug Discovery is used to identify targets, in silico drug design, drug development, predictive analytics, research risk assessment, clinical tracking, and even more.
Machine learning may help maximize treatment by combining biological and clinical evidence with mathematical models and can be used to develop drug testing and probabilistic treatment applications. Computational deep learning research indicates this methodology should be helpful in finding complex models in results. Since biological and clinical data are diverse, deterministic quantic machine learning algorithms offer a reasonable opportunity to advance interpret them. However, one of the major challenges in the drug discovery phase is patient health.
Request Customized Copy of Report @ https://www.fnfresearch.com/customization/ai-in-drug-discovery-market
(We customize your report according to your research need. Ask our sales team for report customization.)
The global AI in the Drug Discovery market is segmented into drug type, technology, end-user, therapeutic area, and region. On the basis of drug type, the global AI in the Drug Discovery market is classified as a small molecule and large molecule. The small molecule segment is expected to record the fastest growth over the predictable period, due to its advantages over the large molecule. On the basis of technology, the global AI in the Drug Discovery market is bifurcated into deep learning, machine learning, and others where machine learning is more dominating over the predictable period. On the basis of end-user, the global AI in the Drug Discovery market is divided into pharmaceutical companies, biopharmaceutical companies, academic, and research institutes, and others where pharmaceutical companies are leading. The global AI in the Drug Discovery industry is categorized into metabolic diseases, cardiovascular diseases, immuno-oncology, neurodegenerative diseases, and others where oncology is at the front, depending on therapeutic areas.
By Drug Type, the segmentation includes small molecule and large molecule. Here small molecule type is accounted for the market share of around 60% and is likely to dominate in the target market. Further, based on the technology it can be segmented into deep learning, machine learning, and other segments in which machine learning accounts for the market share of around 50% and is probable to dominate in the target market. Based on the end-user it can be segmented into pharmaceutical companies, biopharmaceutical companies, academic and research institutions where pharmaceutical companies dominate with around 40% market share in the target market. Depending on the therapeutic area, it can be segmented into metabolic disease, cardiovascular disease, immuno-oncology, oncology, neurodegenerative diseases, and others where oncology controls the target market at about 40% share of the market. It can be segmented into North America, Europe, Asia Pacific, the middle east & Africa, and Latin America, based on the geographic field, where North America dominates the target market at around 50% market share.
Browse the full “AI in Drug Discovery Market By Drug Type (Small Molecule and Large Molecule), By Technology (Deep Learning, Machine Learning, Others), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Academic & Research Institutes, and Others), By Therapeutic Area (Metabolic Diseases, Cardiovascular Diseases, Immuno-Oncology, Oncology, Neurodegenerative Diseases, Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020–2026” report at https://www.fnfresearch.com/ai-in-drug-discovery-market
This report segments the AI in Drug Discovery market as follows:
Global AI in Drug Discovery Market: By Drug Type Segment Analysis
- small molecule
- large molecule
Global AI in Drug Discovery Market: By Technology Segment Analysis
- deep learning
- machine learning
- other segments
Global AI in Drug Discovery Market: By End-user Segment Analysis
- pharmaceutical companies
- biopharmaceutical companies
- academic and research institutions
Global AI in Drug Discovery Market: By Therapeutic Area Segment Analysis
- metabolic disease
- cardiovascular disease
- immuno-oncology
- oncology
- neurodegenerative diseases
Key Insights from Primary Research
- According to our primary respondents, we have analyzed that the global AI in the Drug Discovery market is anticipated to grow annually with a CAGR of nearly 39% till 2026 end.
- It was established through primary research that the global AI in the Drug Discovery market was valued at around USD 830 million in 2019.
- On the basis of drug type, the small molecule led the market in 2019 accounting for around 60% share, in 2019
- Based on technology, the machine learning segment held the largest share in the global AI in the Drug Discovery market, accounted for approximately 50% share in the global market in 2019.
- By the end-user, the pharmaceutical companies segment held a major share in the global AI in the Drug Discovery market in 2019 and is projected to maintain a similar trend over the forecasted period.
- On the basis of therapeutic area segmentation, the oncology category held the leading share of around 25% in 2019.
- On the basis of region segmentation, the North America region held the leading share of around 50% in 2019.
Browse More Related Reports:
Erectile Dysfunction Drugs Market: https://www.fnfresearch.com/erectile-dysfunction-drugs-market
Antimalarial Drugs Market: https://www.fnfresearch.com/antimalarial-drugs-market-by-drug-class-quinine-chloroquine-1128
Diarrhea Drug Market: https://www.fnfresearch.com/diarrhea-drug-market-product-type-adult-diarrhea-drug-857
L-Arabinose Market: https://www.fnfresearch.com/l-arabinose-market-by-product-type-phytoextraction-chemical-654
Anti-Hypertensive Drug Market: https://www.fnfresearch.com/anti-hypertensive-drug-market-by-type-diuretics-ace-694
About Facts & Factors (FnF Research):
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.
Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Follow Us LinkedIn: https://www.linkedin.com/company/fnfresearch
Follow Us Twitter: https://twitter.com/fnfresearch
Contact Us:
Facts & Factors
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
Blog: http://fnfnewsblog.com
Artificial Intelligence
Doosan Robotics Unveils Max-Powered ‘PRIME-SERIES’ of Collaborative Robots at Automate 2024
The New P-SERIES Unleashes Efficiency with a 30 Kilogram Payloadand the Longest Reach of Any Cobot to Date
CHICAGO, May 6, 2024 /PRNewswire/ — Doosan Robotics Inc., one of the world’s leading collaborative robot (cobot) manufacturers, unveiled its newest and most powerful P-SERIES (PRIME-SERIES) today at Automate 2024, bringing to the world of robotics the longest reaching cobot to date.
Today’s P-SERIES announcement by Doosan Robotics was marked by a show floor unveiling of the new P3020 – the world’s most powerful cobot for palletizing in existence. The P3020 offers a payload of 30kg (60lbs) and reach of 2,030mm (80in), bringing the ability to palletize from floor to 2m high (stacking up to 10 layers of boxes approximately 8 inches tall) using its simple fixed base without a lift.
Doosan Robotics has successfully dominated the high-payload cobot market in the 20kg range and above, which includes advanced palletizing solutions. Since launching the H-SERIES in 2022, Doosan Robotics has attracted major global customers such as Schiphol Airport and Wacker Korea, significantly enhancing its global market share by 72%. This year, with the introduction of the P-SERIES, the cobot featuring the highest payload and reach yet, expectations are set to soar beyond previous achievements.
Additional key features of the P-SERIES cobot lineup include lower power consumption compared to similar payload cobots by applying its built-in gravity compensation mechanism, inherent wrist-singularity free, and a 5 degree-of-freedom movement with the 4th axis removed and 6th axis speed increased to 360 degrees/second. Doosan Robotics’ continued priority on optimal safety across its solutions is also fully present in the new P3020. This includes achieving the highest PL (e) and Cat 4 safety ratings to ensure both a max-powered and max-safety experience for users.
The motion platform company’s newly unveiled P3020 palletization cobot will be on full display (Booth #850) at Automate 2024 (May 6-9), alongside the company’s ready-to-sell solutions with best-in class partners in Machine Tending, Palletizing, Welding, and Food & Beverage services.
Driven by its vision to elevate everyday experiences and redefine labor workflows, Doosan Robotics provides a wide, exceptional range of AI cobots aimed to bring about a paradigm shift across various sectors, such as palletizing, manufacturing, logistics, food & beverage, architecture, and service industries. These cutting-edge solutions transcend the constraints of conventional robotics, adeptly maneuvering through intricate scenarios while infusing tasks with enhanced efficiency, safety, and ingenuity. Moreover, the AI system boasts continuous learning capabilities, effortlessly updating its model by autonomously downloading required modules for smooth integration.
“As a motion platform company, Doosan Robotics is meeting the ever-growing need for cobots to mimic human motion, powerfully and safely,” said William Ryu, CEO at Doosan Robotics. “The robotics industry continues to grow at an exponential pace and our lineup of software, cobots and AI differentiates us in our mission to develop cobots with a ‘max-powered, max-efficiency, max-safety’ mindset.”
For more details and videos on the new P3020 cobot by Doosan Robotics, please visit the Doosan Robotics YouTube channel here. For more info, images, and other assets regarding Doosan Robotics’ Automate 2024 overall presence, please visit the press kit here or contact [email protected].
ABOUT DOOSAN ROBOTICSDoosan Robotics is a global leader in collaborative robot solutions, embodying the principle of ‘Innovation in every motion, revolutionizing the way we work.’ Doosan robots, known for world-class safety and precision, enhance task efficiency across various sectors from manufacturing to service, enabling people to focus on more valuable work. More information about Doosan Robotics is available at https://www.doosanrobotics.com/en/.
Photo – https://mma.prnewswire.com/media/2405465/Doosan_Robotics_Unveils_Max_Powered_PRIME_SERIES.jpg
Logo – https://mma.prnewswire.com/media/2403399/Doosan_Robotics_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/doosan-robotics-unveils-max-powered-prime-series-of-collaborative-robots-at-automate-2024-302136958.html
Artificial Intelligence
Enghouse announces expansion of our cloud contact center technology in the Middle East through our partnership with Voxtron
MARKHAM, ON, May 6, 2024 /PRNewswire/ — Enghouse Interactive, a global leader in contact center and video technology solutions, is proud to announce a strategic partnership with Voxtron, the premier provider of call center solutions in the Middle East. This collaboration is marked by Voxtron’s introduction of the innovative Voxvantage Cloud Contact Center as a Service (CCaaS), leveraging advanced contact center technology from Enghouse.
The Official Launch will take place at the Grand Hyatt Dubai. Industry participants and media are invited to RSVP to attend by emailing [email protected].
Date: 9th May 2024 Time: 6:00 PM to 10:00 PM Venue: Grand Hyatt Dubai, RSVP: [email protected]
Voxvantage CCaaS marks a significant advancement for Enghouse Systems, underscoring a commitment to enhancing customer experiences throughout the region. Hosted on the robust data center infrastructure of Moro Hub, Voxtron guarantees exceptional reliability, security, and scalability.
The launch will feature distinguished speakers, including Tracy Reynolds, Canadian Consul General in Dubai, Vincent Mifsud, Global President of Enghouse Systems, and Arif AlMalik, Chief Digital Products Officer of Moro Hub. They will explore the transformative potential of contact solutions in improving customer experience (CX) in the Middle East.
Mr. Mifsud expressed his enthusiasm about the partnership, stating, “We are excited to collaborate with Voxtron and Moro Hub. This partnership is crucial as we aim to provide our call center technology, enhance our presence across the Middle East by providing customers with leading technology that improves customer experiences.”
The event will also offer excellent networking opportunities and insightful discussions on the future of customer engagement solutions.
About Enghouse Interactive:
Enghouse Interactive, a subsidiary of Enghouse Systems Limited, is a global leader in contact center software and video technology solutions offering its customers and partners the valuable advantage of choice. Enghouse Interactive empowers businesses to transform contact centers from cost centers into powerful growth engines by simplifying complex integrations through open standards and supporting various telephony technologies to ensure seamless customer accessibility across channels and locations.
About Voxtron:
Voxtron Middle East is headquartered in Dubai, U.A.E., and has a global presence with offices and affiliates in Qatar, India, Germany, Austria, Belgium, Italy, Turkey, Tunisia, Hong Kong, Portugal, and Thailand. Voxtron has been delivering cost-effective customer engagement optimization solutions in collaboration with leading technology vendors such as Enghouse Interactive, SAGE, Verint, and Clarabridge, for over a decade. This extensive portfolio positions Voxtron as a unique provider capable of delivering complete, fully-featured solutions to customers and partners.
Enghouse Video Contact: Tim Peters, VP, Global Demand Generation Leader, Enghouse Systems, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/enghouse-announces-expansion-of-our-cloud-contact-center-technology-in-the-middle-east-through-our-partnership-with-voxtron-302136981.html
Artificial Intelligence
Appdome Named “Editor’s Choice for Mobile App Security” in Coveted Global InfoSec Awards during RSA Conference 2024
Appdome Wins in 12th Annual Global InfoSec Awards at #RSAC 2024
SAN FRANCISCO, May 6, 2024 /PRNewswire/ — Appdome, the mobile app economy’s one-stop shop for mobile app defense, is proud to announce it has won Editor’s Choice for Mobile App Security from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine.
The Appdome platform is the first and only full lifecycle mobile app defense platform to automatically build, monitor and respond with any or all of 300+ mobile app defenses including security, anti-fraud, anti-malware, anti-cheat, anti-bot, geo compliance and social engineering for any mobile app in minutes with no SDK or coding required – all within the CI/CD pipeline. As a mobile app security engine for DevOps, Appdome enables mobile app developers, even those lacking security expertise, with an easy and fast way to secure all Android & iOS apps without any additional work. By automating security in the mobile pipeline, Appdome eliminates the cost and complexity of manually coding security, fraud and compliance features so mobile brands can confidently ship secure mobile apps faster with always-on protections to meet their critical mobile business needs.
“We’re proud to be recognized as Editor’s Choice for Mobile App Security by Cyber Defense Magazine in its 12th year of awarding the most prestigious and coveted cybersecurity award in the world,” said Tom Tovar, co-creator and CEO of Appdome. “With organizations battling unnecessary complexity from point products, the Appdome platform approach to mobile defense is leading the way to unify 300+ protections across security, anti-fraud, bot defense, mobile EDR, and compliance for all internal (employee) and external (consumer) facing mobile applications under a single pane of glass.”
“We scoured the globe looking for cybersecurity innovators that could make a huge difference and potentially help turn the tide against the exponential growth in cyber-crime. Appdome is absolutely worthy of Editor’s Choice for Mobile App Security coveted award and consideration for deployment in your environment,” said Yan Ross, Global Editor of Cyber Defense Magazine.
Appdome and all award winners located here: http://www.cyberdefenseawards.com/
Appdome continues to deliver waves of innovation in 2024 including:
Appdome Unveils World’s first Agentless Mobile EDR & MTDAppdome MOBILEBot ProtectionAppdome World’s First Real-Time Defense for Social EngineeringAppdome Revolutionizes Geo Defense for Mobile BrandsPlease join Appdome at the RSA Conference 2024 booth #2339 to see the award winning Appdome Platform in action!
Learn more at www.appdome.com.
About AppdomeThe Appdome mission is to protect every mobile app in the world and the people who use mobile apps in their lives and at work. Appdome provides the mobile industry’s only Unified Mobile App Defense platform, powered by a patented mobile coding engine, Threat-Events™ Threat-Aware UX/UI Control and ThreatScope™ Mobile XDR. Using Appdome, mobile brands eliminate complexity, ship faster and save money by delivering 300+ Certified Secure™ mobile app security, anti-malware, anti-fraud, mobile anti-bot, anti-cheat, geo compliance, MiTM attack prevention, code obfuscation, social engineering and other protections in Android and iOS apps with ease, inside the mobile DevOps and CI/CD pipeline. Leading financial, healthcare, government and m-commerce brands use Appdome to protect Android and iOS apps, mobile customers and mobile businesses globally. Appdome holds several patents including U.S. Patents 9,934,017 B2, 10,310,870 B2, 10,606,582 B2, 11,243,748 B2 and 11,294,663 B2. Additional patents pending.
About Cyber Defense MagazineCyber Defense Magazine is the premier source of cyber security news and information for InfoSec professions in business and government. We are managed and published by and for ethical, honest, passionate information security professionals. Our mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products, and services in the information technology industry. We deliver electronic magazines every month online for free, and special editions exclusively for the RSA Conferences. CDM is a proud member of the Cyber Defense Media Group. Learn more about us at https://www.cyberdefensemagazine.com and visit https://www.cyberdefensetv.com and https://www.cyberdefenseradio.com to see and hear some of the most informative interviews of many of these winning company executives. Join a webinar at https://www.cyberdefensewebinars.com and realize that infosec knowledge is power.
Logo – https://mma.prnewswire.com/media/772169/4688418/AppDome_Logo_9_27_23.jpg
View original content:https://www.prnewswire.co.uk/news-releases/appdome-named-editors-choice-for-mobile-app-security-in-coveted-global-infosec-awards-during-rsa-conference-2024-302136929.html
-
Artificial Intelligence3 days ago
CleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Uncategorized7 days ago
Intel unveils AI-Platform Innovation for Paris 2024
-
Artificial Intelligence7 days ago
SUNRATE partners with YeePay to empower Chinese companies to navigate global expansion
-
Uncategorized4 days ago
Improving the Developer Journey in Crafting Artificial Intelligence Applications
-
Artificial Intelligence5 days ago
Appdome Unveils World’s First Agentless Mobile EDR & MTD
-
Uncategorized4 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence4 days ago
5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence4 days ago
Bitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options